Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL, follicular lymphoma, and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, amyloidosis, and solid tumors; Tisotumab vedotin, HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; HuMax-TAC-ADC (ADCT-301) to treat lymphoma and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for metastatic solid tumors; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 for MM; and AMG 714 for the treatment of celiac disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNMSF
Previous Symbol
CUSIPN/A
Phone45-7020-2728
Debt
Debt-to-Equity RatioN/A
Current Ratio19.94
Quick Ratio19.94
Price-To-Earnings
Trailing P/E Ratio59.52
Forward P/E Ratio48.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$359.31 million
Price / Sales27.41
Cash Flow$2.7769 per share
Price / Cash Flow57.87
Book Value$15.57 per share
Price / Book10.32
Profitability
EPS (Most Recent Fiscal Year)$2.70
Net Income$167.62 million
Net Margins48.74%
Return on Equity19.83%
Return on Assets18.82%
Miscellaneous
Employees309
Outstanding Shares61,280,000
Market Cap$9.72 billion
OptionableNot Optionable
Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions
What is Genmab A/S's stock symbol?
Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."
How were Genmab A/S's earnings last quarter?
Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings data on Wednesday, November, 5th. The company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.45 by $0.02. The business had revenue of $45.65 million for the quarter, compared to the consensus estimate of $53.94 million. Genmab A/S had a return on equity of 19.83% and a net margin of 48.74%. View Genmab A/S's Earnings History.
When is Genmab A/S's next earnings date?
What is the consensus analysts' recommendation for Genmab A/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genmab A/S.
Has Genmab A/S been receiving favorable news coverage?
Media headlines about GNMSF stock have been trending somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genmab A/S earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of Genmab A/S's key competitors?
Some companies that are related to Genmab A/S include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Beigene (BGNE) and Sarepta Therapeutics (SRPT).
Who are Genmab A/S's key executives?
Genmab A/S's management team includes the folowing people:
- Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 57)
- Mr. David A. Eatwell, Exec. VP & CFO (Age 57)
- Dr. Judith Klimovsky, Exec. VP & Chief Devel. Officer (Age 60)
- Ms. Jane Juel, Sr. Director of Operations & Resource Management
- Mr. Peter Ros, Sr. Director of Fin. & Accounting and R&D Operations
How do I buy shares of Genmab A/S?
Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genmab A/S's stock price today?
One share of GNMSF stock can currently be purchased for approximately $160.70.
How big of a company is Genmab A/S?
Genmab A/S has a market capitalization of $9.72 billion and generates $359.31 million in revenue each year. The company earns $167.62 million in net income (profit) each year or $2.70 on an earnings per share basis. Genmab A/S employs 309 workers across the globe.
What is Genmab A/S's official website?
How can I contact Genmab A/S?
Genmab A/S's mailing address is BREDGADE 34E, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected]
MarketBeat Community Rating for Genmab A/S (OTCMKTS GNMSF)
MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.
